

## Erratum to: *ACE* deletion polymorphism is associated with a high risk of non-infectious pulmonary complications after stem cell transplantation

Mitsuki Miyamoto · Makoto Onizuka · Shinichiro Machida · Masako Toyosaki · Jun Amaki · Yasuyuki Aoyama · Hidetsugu Kawai · Ai Sato · Naoki Hayama · Yoshiaki Ogawa · Hiroshi Kawada · Kiyoshi Ando

Published online: 14 October 2014  
© The Japanese Society of Hematology 2014

**Erratum to: Int J Hematol (2014) 99:175–183**  
**DOI 10.1007/s12185-013-1494-6**

Unfortunately, Figs. 2 and 3 were swapped in the original publication of the article. The figures should appear as below.



---

The online version of the original article can be found under doi:[10.1007/s12185-013-1494-6](https://doi.org/10.1007/s12185-013-1494-6).

---


M. Miyamoto · M. Onizuka (✉) · S. Machida · M. Toyosaki · J. Amaki · Y. Aoyama · H. Kawai · A. Sato · Y. Ogawa · H. Kawada · K. Ando  
Department of Hematology and Oncology, Tokai University School of Medicine, 143 shimokasuya, Isehara, Kanagawa 259-1143, Japan  
e-mail: [moni5@mac.com](mailto:moni5@mac.com)

N. Hayama  
Department of Pulmonary Medicine, Tokai University School of Medicine, Tokyo, Japan



**Fig. 2** Association of ACE polymorphism to clinical outcomes. **a** Cumulative incidence curve of transplantation-related mortality (TRM) among allogeneic HSCT patients comparing the ACE insertion genotypes and deletion polymorphisms (HR 1.53,  $P = 0.32$ ,

95 % CI 0.7–3.5). **b** Cumulative incidence curve of relapse among 140 allogeneic HSCT patients diagnosed with malignant disease comparing the ACE insertion genotypes and deletion polymorphisms (HR 0.4,  $P = 0.085$ , 95 % CI 0.1–1.1)



**Fig. 3** NIPC and ACE polymorphisms. Cumulative incidence curve of NIPC among allogeneic HSCT patients comparing the ACE insertion genotypes and deletion polymorphisms (HR 9.03,  $P < 0.0001$ , 95 % CI 3.4–24.2)